KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Equity Average (2018 - 2025)

Historic Equity Average for Takeda Pharmaceutical (TAK) over the last 8 years, with Q3 2025 value amounting to $47.9 billion.

  • Takeda Pharmaceutical's Equity Average changed N/A to $47.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 billion, marking a year-over-year change of. This contributed to the annual value of $48.0 billion for FY2025, which is 154.41% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Equity Average of $47.9 billion as of Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Equity Average ranged from a high of $49.7 billion in Q3 2023 and a low of $45.9 billion during Q1 2023
  • For the 5-year period, Takeda Pharmaceutical's Equity Average averaged around $47.9 billion, with its median value being $47.9 billion (2022).
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 1182.79% in 2021, then crashed by 632.11% in 2025.
  • Takeda Pharmaceutical's Equity Average (Quarter) stood at $47.6 billion in 2021, then decreased by 3.09% to $46.2 billion in 2022, then increased by 2.44% to $47.3 billion in 2023, then grew by 4.87% to $49.6 billion in 2024, then decreased by 3.36% to $47.9 billion in 2025.
  • Its Equity Average was $47.9 billion in Q3 2025, compared to $46.5 billion in Q2 2025 and $47.1 billion in Q1 2025.